DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma
Jingchun Wang, Yu Chen, Yanquan Xu, Jiangang Zhang, Shuai Yang, Yu Zhou, Juan Lei, Ran Ren, Yang Chen, Huakan Zhao, Yongsheng Li, Shiming Yang
Abstract
Our findings offer valuable insights into the mechanisms underlying DNASE1L3's role in sorafenib sensitivity and position DNASE1L3 as a promising predictive biomarker and target for improving outcomes in combination therapy for HCC.
Topics & Concepts
Hepatocellular carcinomaMedicineCancer researchOncologyCombination therapyInternal medicineAutophagy in Disease and TherapyUbiquitin and proteasome pathwaysRNA modifications and cancer